Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:

Thursday, April 27, 2017

Review Finds No Benefit to Aspirin for Preserving Cognitive Function

So what the fuck is the protocol for preserving cognitive function? Or is your doctor so incompetent that no research is read on this and s/he doesn't have the brains to hire an analyst to summarize research results needed to get their stroke patients to 100% recovery?
April 20, 2017
HOBOKEN, NJ -- April 20, 2017 -- An analysis of published studies found no evidence that low- dose aspirin buffers against cognitive decline or dementia or improves cognitive test scores.
The review and meta-analysis, published in the Journal of the American Geriatrics Society, included 8 studies with 36,196 participants (mean age, 65 years) who did not have cognitive impairment at baseline.
Nicola Veronese, MD, Aging Section, Institute of Neurosciences, Italian Research Council, Padova, Italy, and colleagues wanted to investigate whether low-dose aspirin (<300 mg/day) can influence the onset of cognitive impairment or dementia in observational studies and improve cognitive test scores in randomised controlled trials (RCTs) in participants without dementia.
After adjusting for a median of 3 potential confounders over a median follow-up period of 6 years, chronic use of low-dose aspirin was not associated with onset of dementia or cognitive impairment (5 studies, n = 26,159; odds ratio [OR] = 0.82; 95% confidence interval [CI], 0.55-1.22; P = .33; I2 = 67%).
In 3 RCTs (n = 10,037; median follow-up 5 years), the use of low-dose aspirin was not associated with significantly better global cognition (95% CI, 0.04-0.05; P = .84, I2 = 0%) in individuals without dementia.
Adherence was lower in participants taking aspirin than in controls, and the incidence of adverse events was higher.
“Additional studies are needed to test the possibility that low-dose aspirin has beneficial effects when taken over a longer period and at an earlier age,” said Dr. Veronese.

No comments:

Post a Comment